Long-acting HIV fusion inhibitor albuvirtide combined with ritonavir-boosted lopinavir for HIV-1-infected patients after failing the first-line antiretroviral therapy: 48-week randomized, controlled, phase 3 non-inferiority TALENT study

Publication date: September 2022Source: Journal of Infection, Volume 85, Issue 3Author(s): Bin Su, Cheng Yao, Qing-Xia Zhao, Wei-Ping Cai, Min Wang, Hong-Zhou Lu, Ting-Ting Mu, Yuan-Yuan Chen, Li Liu, Hui Wang, Yun He, Yu-Huang Zheng, Ling-Hua Li, Jin-…